Diligence memo · auto-generated · as of July 2, 2026
Rapamycin Holdings, Inc.
Rapamycin Holdings, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Rapamycin Holdings, Inc. operates in Pharmaceuticals, based in SAN ANTONIO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rapamycin Holdings, Inc. has raised $18M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2019-07-01.
Most recent recorded round closed around 2019-07-01.
Valuation (modeled)modeled
Provath models Rapamycin Holdings, Inc. at approximately $217M (range $8.0M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.42× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era. Within the normal band (142% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 7.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 64% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.